UBS AM
TPTX

UBS AM’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

UBS AM’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-48,759
Closed -$3.67M – 2796
2022
Q2 		$3.67M Buy
48,759
+4,796
+11% +$213K ﹤0.01% 1331
2022
Q1 		$1.18M Hold
43,963
– – ﹤0.01% 2048
2021
Q4 		$2.1M Sell
43,963
-946
-2% -$42.3K ﹤0.01% 1857
2021
Q3 		$2.98M Buy
44,909
+322
+0.7% +$22.9K ﹤0.01% 1645
2021
Q2 		$3.48M Buy
44,587
+2,149
+5% +$159K ﹤0.01% 1569
2021
Q1 		$4.01M Buy
42,438
+5,777
+16% +$687K ﹤0.01% 1432
2020
Q4 		$4.47M Buy
36,661
+8,300
+29% +$909K ﹤0.01% 1343
2020
Q3 		$2.48M Sell
28,361
-722
-2% -$50.3K ﹤0.01% 1460
2020
Q2 		$1.88M Buy
29,083
+19,583
+206% +$1.13M ﹤0.01% 1541
2020
Q1 		$424K Sell
9,500
-5,178
-35% -$275K ﹤0.01% 2034
2019
Q4 		$914K Buy
+14,678
New +$698K ﹤0.01% 1957

UBS AM's TPTX Position: Q3 2022 in Review

UBS AM sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 48,759 shares — an estimated $3.67M sold.

UBS AM first reported a position in TPTX in Q4 2019 and held it in 11 quarters. The position peaked at $4.47M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • UBS AM reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • UBS AM sold 48,759 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $3.67M.
  • UBS AM first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
  • UBS AM's Turning Point Therapeutics, Inc. Common Stock position peaked at $4.47M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on UBS AM's 13F filing for Q3 2022, filed 14 Nov 2022.